Back to top
more

Axsome Therapeutics (AXSM)

(Delayed Data from NSDQ)

$71.71 USD

71.71
272,230

+0.19 (0.27%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $71.76 +0.05 (0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for AXSM

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for Axsome Therapeutics, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 386 201 86 184 220
Receivables 95 38 0 0 0
Notes Receivable 0 0 0 0 0
Inventories 15 4 0 0 0
Other Current Assets 8 3 0 0 0
Total Current Assets 504 246 87 184 220
Net Property & Equipment 1 1 0 0 0
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 11 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 65 70 0 0 0
Deposits & Other Assets 0 15 0 0 0
Total Assets 588 331 88 186 221
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 3
Accounts Payable 41 39 13 14 11
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 91 52 9 9 11
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 6 6 0 0 0
Total Current Liabilities 139 97 23 23 24
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 178 94 49 48 17
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 73 31 0 0 0
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 397 222 72 72 42
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 1,027 706 425 393 355
Retained Earnings -836 -596 -409 -279 -176
Other Equity 0 0 0 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 191 110 16 114 179
Total Liabilities & Shareholder's Equity 588 331 88 186 221
Total Common Equity 191 110 16 114 179
Shares Outstanding 47.30 43.40 37.60 37.30 34.50
Book Value Per Share 4.04 2.52 0.42 3.05 5.18

Fiscal Year End for Axsome Therapeutics, Inc falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 386 417 437 247
Receivables NA 95 78 67 45
Notes Receivable NA 0 0 0 0
Inventories NA 15 10 9 8
Other Current Assets NA 8 7 6 5
Total Current Assets NA 504 512 520 304
Net Property & Equipment NA 1 1 1 1
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 11 14 15 16
Deferred Charges NA 0 0 0 0
Intangibles NA 65 67 69 68
Deposits & Other Assets NA 0 0 0 0
Total Assets NA 588 601 612 389
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 41 29 43 36
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 91 78 65 59
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 6 7 6 6
Total Current Liabilities NA 139 115 115 101
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 0 0 0 0
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 178 177 177 148
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 32 34 29
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 397 331 333 277
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 1,027 1,006 954 719
Retained Earnings NA -836 -737 -675 -608
Other Equity NA 0 0 0 0
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 191 270 279 112
Total Liabilities & Shareholder's Equity NA 588 601 612 389
Total Common Equity 0 191 270 279 112
Shares Outstanding 47.30 47.30 47.10 43.50 43.50
Book Value Per Share 0.00 4.04 5.72 6.41 2.57